- Home
- Automated
- List of product information
- MOXIPEN CAPSULE 250 MG [SIN06951P]
MOXIPEN CAPSULE 250 MG [SIN06951P]
Active ingredients: MOXIPEN CAPSULE 250 MG
Product Info
MOXIPEN CAPSULE 250 MG
[SIN06951P]
Product information
Active Ingredient and Strength | AMOXYCILLIN TRIHYDRATE EQV AMOXYCILLIN - 250 MG |
Dosage Form | CAPSULE |
Manufacturer and Country | XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD - MALAYSIA |
Registration Number | SIN06951P |
Licence Holder | APEX PHARMA MARKETING PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J01CA04 |
Indications
Moxipen is a broad spectrum antibiotic indicated for the treatment of commonly occurring bacterial infections such as:
Upper respiratory tract infections e.g. ear, nose and throat infections, otitis media.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia.
Gastrointestinal tract infections e.g. typhoid and paratyphoid fever.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, septic abortion, puerperal sepsis.
Skin and soft tissue infections.
Biliary tract infections.
Bone infections.
Pelvic infections.
Gonorrhoea (non-penicillinase producing strains).
Septicaemia.
Endocarditis.
Meningitis.
Peritonitis.
Dental abscess (as an adjunct to surgical management).
Helicobacter pylori eradication in peptic (duodenal and gastric) ulcer disease.
Infections such as septicaemia, endocarditis and meningitis due to susceptible organisms should be treated initially with high doses of a parenteral therapy and, where appropriate, in combination with another antibiotic.
Prophylaxis of endocarditis: Moxipen may be used for the prevention of bacteraemia associated with procedures such as dental extraction, in patients at risk of developing endocarditis (see Table in Dosage and Administration).
Dosage and Administration
Moxipen is stable in the presence of gastric acid and may be given before or after food.
Adults:
Standard adult dosage: 250 mg every 8 hours, increasing to 500 mg every 8 hours for more severe infections.
High dosage therapy (maximum recommended oral dosage 6 g daily in divided doses): A dosage of 3 g twice daily is recommended in appropriate cases for the treatment of severe or recurrent purulent infection of the respiratory tract.
Short course therapy:
Simple acute urinary tract infection: two 3 g doses with 10 to 12 hours between the doses.
Dental abscess: two 3 g doses with 8 hours between the doses.
Gonorrhoea: single 3 g dose.Helicobacter eradication in peptic (duodenal and gastric) ulcer disease:
Moxipen is recommended at a dose of twice daily in association with a proton pump inhibitor and antimicrobial agents as detailed below:
Omeprazole 40 mg daily, Amoxicillin 1 g twice a day, Clarithromycin 500 mg twice a day for 7 days.
or Omeprazole 40 mg daily, Amoxicillin 750 mg to 1 g twice a day, Metronidazole 400 mg 3 times a day for 7 days.
Children
Moxipen Powder for Oral Suspension is recommended for children under 6 months of age.

In severe or recurrent acute otitis media, especially where compliance may be a problem, 750 mg twice a day for 2 days may be used as an alternative course of treatment in children aged 3 to 10 years.
Patients with renal impairment:
In renal impairment, the excretion of the antibiotic will be delayed and, depending on the degree of impairment, it may be necessary to reduce the total daily dosage according to the following scheme:





Parenteral therapy is indicated if the oral route is considered impracticable or unsuitable, and particularly for the urgent treatment of severe infection.
In renal impairment the excretion of the antibiotic will be delayed and depending on the degree of impairment, it may be necessary to reduce the total daily dosage.
Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.
Contraindications
Moxipen is contraindicated in patients allergic to penicillins and in patients with infectious mononucleosis.
